Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sonoma Biotherapeutics

Request full access

Best-in-class regulatory T cell therapy, delivering long-lasting, highly effective, curative treatments across a spectrum of autoimmune and degenerative diseases

South San Francisco, United StatesFounded 2019Biotech & Life Sciences

About Sonoma Biotherapeutics

Sonoma Bio is a biotechnology startup that operates in the healthcare sector, specifically in the field of autoimmune and inflammatory disease treatment. The company's primary focus is on developing living cell therapies that aim to restore balance to the immune system and potentially cure autoimmune diseases. This innovative approach utilizes the body's own immune response regulators to correct an overactive immune system, a common issue in autoimmune conditions.

Sonoma Bio's business model is centered around the research and development of these therapies. The company leverages the extensive research of its founders and a team of dedicated scientists to pioneer new treatments in Treg biology and cell therapy. The company's revenue is likely generated through partnerships with healthcare providers and institutions, as well as potential future sales of their developed therapies.

The company's target market includes patients suffering from autoimmune diseases and their care partners. Sonoma Bio is driven by a mission to not only find a cure for these diseases but also to significantly improve the quality of life for those affected by them.

The company's approach is rooted in scientific knowledge and collaboration, balancing these with a capable team that can execute their vision. They are committed to meeting the needs of patients and care partners, and their work is firmly grounded in science.

Source: Dealroom company data

At a glance

Status
Operational
Employees
63
Open positions
1
Dealroom signal
61.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Nov 2025 $300K — ScaleReady ↗
SERIES BOther financing Aug 2021 $265M $1.1B 8VC · Mirae Asset Capital · Frazier Healthcare Partners · Lilly Asia Ventures ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Sonoma Biotherapeutics website traffic

Latest recorded traffic for Sonoma Biotherapeutics is 7.5K monthly website visits, up 92.3% over the last three months. Sonoma Biotherapeutics's team declined 43.8% over the past year.

Latest monthly visits7.5K 3-month web change+92.3% 1-year team growth-43.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sonoma Biotherapeutics in the South San Francisco ecosystem

Live from Dealroom

The Sonoma Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

25 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • ScaleReady

Series A22 investors entered at this stage

  • 8VC
  • Lyell Immunopharma
  • ARCH Venture Partners
  • Milky Way Ventures
  • JDRF T1D Fund
  • Alexandria Venture Investments
  • Lilly Asia Ventures
  • Lifeforce Capital
  • Octagon Capital Partners
  • Ally Bridge Group
  • Mirae Asset Capital
  • Frazier Healthcare Partners
  • Janus Henderson Investors
  • Vertex Ventures HC
  • Timefolio Capital
  • Fidelity Investments
  • Casdin Capital
  • Osage University Partners
  • ArrowMark Partners
  • Avidity Partners
  • Deep Track Capital
  • Piper Heartland Healthcare Capital

Other known investors2 additional known investors

  • University of California, San Francisco
  • University of Washington
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.8%
🇨🇦 Canada1.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sonoma Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sonoma Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.